Spironolactone
Product Images NDC 10544-499

4 FDA label images from Blenheim Pharmacal, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Spironolactone (NDC 10544-499). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Blenheim Pharmacal, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Lable 25mg 90ct (Label Spironolactone Tabs 25mg Bpi(10544 499 90) Amneal(53746 511 10) Rev1)

Lable 25mg 90ct (Label Spironolactone Tabs 25mg Bpi(10544 499 90) Amneal(53746 511 10) Rev1)
Label for Spironolactone Tablets USP 25mg by Blenheim Pharmacal, Inc. The package contains 90 tablets and is labeled Rx only. Storage instructions specify a controlled room temperature between 20°-25°C (68°-77°F) and keeping the product in a tight, light-resistant container, out of reach of children. The label includes NDC 10544-499-90 and manufacturing details.*
FDA Label Image

Structure (Spironolactone Tablets Usp 1)

Structure (Spironolactone Tablets Usp 1)
Chemical structure diagram of Spironolactone showing its molecular framework with characteristic rings and functional groups including a lactone ring and ketone moieties.*
FDA Label Image

Figure 2 (Spironolactone Tablets Usp 2)

Figure 2 (Spironolactone Tablets Usp 2)
A line graph showing probability over time in months comparing two groups: Spironolactone (n=822) and Placebo (n=841). The y-axis represents probability, and the x-axis represents months, with a log-rank p-value of < 0.001 indicated on the chart.*
FDA Label Image

Figure 3 (Spironolactone Tablets Usp 3)

Figure 3 (Spironolactone Tablets Usp 3)
A forest plot illustrating subgroup analyses from a clinical study, showing hazard ratios (HR) with 95% confidence intervals (CI) for Spironolactone compared to placebo. Subgroups include age, sex, race, LVEF percentage, heart failure type, NYHA class, diabetes status, serum creatinine levels, creatinine clearance, potassium levels, digoxin use, ACE inhibitor use, and beta blocker use. The plot indicates effects across these categories with HR values and participant counts (N).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.